JNJennifer Nicki

Jennifer Nicki

*This is an algorithmically generated author record based on publicly available information.

Jennifer Nicki has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations

    by Irina Yurgelonis, Devendra K. Rai, Zhenghui Li, Brittany Washington, Patricia McMonagle, Stephen Noell, Olga Plotnikova, Jennifer Nicki, Timothy K. Craig, Qingyi Yang, et al.


  • Open Access

    Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca2+ dependent allosteric binding site

    by Leslie A. Dakin, Li Xing, Justin Hall, Weidong Ding, Felix F. Vajdos, Jeffrey W. Pelker, Simeon Ramsey, Paul Balbo, Parag V. Sahasrabudhe, Mary Ellen Banker, et al.

    Peptidylarginine deiminases (PAD1-4) are calcium dependent enzymes responsible for protein citrullination, a post-translational modification converting arginine residues to citrulline. Elevated levels of citrullinated proteins have been associated with rheumatoid arthritis, neurodegenerative diseases, and cancers. Though highly selective PAD4 inhibitors have been described, inhibitors to the broader family currently are limited to covalent substrate analogs. Herein, we describe an allosteric binding pocket common to PAD1-4 suitable for the identification of potent, non-covalent enzyme inhibitors. A ligand-based virtual screen is utilized to identify a PAD4 inhibitor for which surface plasmon resonance confirms target binding but non-competitively with a known PAD4 ligand. We further show through co-crystal structure analysis that the ligand binds PAD4 at an allosteric pocket resulting in stabilization of a catalytically inactive, calcium-deficient enzyme conformation. A ligand designed based on this site potently inhibits all four PAD isozymes and prevents protein citrullination in neutrophils with a broader protein repertoire than observed with a PAD4-selective inhibitor.


  • Open Access

    In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance

    by Yuao Zhu, Irina Yurgelonis, Stephen Noell, Qingyi Yang, Shunjie Guan, Zhenghui Li, Li Hao, Hussin Rothan, Devendra K. Rai, Patricia McMonagle, et al.

    To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M pro inhibitor nirmatrelvir (Paxlovid active component) was conducted. Six M pro mutation patterns containing T304I alone or in combination with T21I, L50F, T135I, S144A, or A173V emerged, with A173V+T304I and T21I+S144A+T304I mutations showing >20-fold resistance each. Biochemical analyses indicated inhibition constant shifts aligned to antiviral results, with S144A and A173V each markedly reducing nirmatrelvir inhibition and M pro activity. SARS-CoV-2 surveillance revealed that in vitro resistance–associated mutations from our studies and those reported in the literature were rarely detected in the Global Initiative on Sharing All Influenza Data database. In the Paxlovid Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial, E166V was the only emergent resistance mutation, observed in three Paxlovid-treated patients, none of whom experienced COVID-19–related hospitalization or death.


  • Top Cited Papers
    Open Access

    Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants

    by Samantha E. Greasley, Stephen Noell, Olga Plotnikova, RoseAnn Ferre, Wei Liu, Ben Bolanos, Kimberly Fennell, Jennifer Nicki, Tim Craig, Yuao Zhu, et al.


  • Open Access

    Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants

    by Samantha E Greasley, Stephen Noell, Olga Plotnikova, Rose Ann Ferre, Wei Liu, Ben Bolanos, Kimberly Fennell, Jennifer Nicki, Tim Craig, Yuao Zhu, et al.

    The COVID-19 pandemic continues to be a public health threat with emerging variants of SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2 and the active protease inhibitor in PAXLOVID ™ (nirmatrelvir tablets and ritonavir tablets). We evaluated the in vitro catalytic activity and in vitro potency of nirmatrelvir against the main protease (M pro ) of prevalent variants of concern (VOC) or variants of interest (VOI): Alpha (α, B.1.1.7), Beta (β, B.1.351), Delta (δ, B1.617.2), Gamma ( γ , P.1), Lambda (λ, B.1.1.1.37/C37), Omicron (o, B.1.1.529) as well as the original Washington or wildtype strain. These VOC/VOI carry prevalent mutations at varying frequencies in the M pro specifically for: α, β, γ (K90R), λ (G15S) and o (P132H). In vitro biochemical enzymatic assay characterization of the enzyme kinetics of the mutant M pros demonstrate that they are catalytically comparable to wildtype. Nirmatrelvir has similar potency against each mutant M pro including P132H that is observed in the Omicron variant with a Ki of 0.635 nM as compared to a Ki of 0.933nM for wildtype. The molecular basis for these observations were provided by solution-phase structural dynamics and structural determination of nirmatrelvir bound to the o, λ and β Mpro at 1.63 - 2.09 Å resolution. These in vitro data suggest that PAXLOVID has the potential to maintain plasma concentrations of nirmatrelvir many-fold times higher than the amount required to stop the SARS-CoV-2 VOC/VOI, including Omicron, from replicating in cells (1).